(PharmaNewsWire.Com, March 23, 2018 ) A Global Hyperhidrosis Market Landscape Assessment: Trends, Forecasts and Opportunities in a Growing Market
Summary
GBI Research's latest report, "A Global Hyperhidrosis Market Landscape Assessment: Trends, Forecasts and Opportunities in a Growing Market" provides an in-depth assessment of the current trends in the global hyperhidrosis market, with a particular focus on primary axillary hyperhidrosis. This report also assesses the commercial landscape through multilevel analytics that include data split by stage of development, molecular target, molecule type and route of administration.
Hyperhidrosis is a chronic disorder of excessive sweating beyond thermoregulatory needs and environmental conditions. It commonly arises in childhood and adolescence, and can affect patients for many years. Most cases of hyperhidrosis involve areas of high eccrine (sweat gland) density, particularly the armpits, palms and soles, and less often the facial area. According to the International Hyperhidrosis Society (IHS), the global prevalence population of hyperhidrosis is 367 million. The US has the most hyperhidrosis cases among the major developed countries covered in this report. Hyperhidrosis occurs in men and women equally, and can present at any age.
A limited number of approved products are available to treat primary axillary hyperhidrosis. Anticholinergics, antiperspirants and other botulinum toxin products, which are currently used off-label to treat the condition, are major competitors for available approved products. Existing therapies for the treatment of primary axillary hyperhidrosis have the ability to slow down the symptoms of the disease, but are unable to provide a complete cure. Moreover, the primary axillary hyperhidrosis pipeline lacks novelty and is very weak in terms of number of molecules in the development.
The IHS recommends the use of approved medical device therapies as a permanent therapy for primary axillary hyperhidrosis. A shift from drug therapy to approved medical device therapy-which can provide a permanent cure for the disease-is likely to restrict the growth of the overall primary axillary hyperhidrosis drug market.
Results from GBI Research's secondary research efforts have been integrated and amalgamated with our own analytical views to create a cohesive, insightful and objective assessment, examining the current state of the primary axillary hyperhidrosis therapy market and its future commercial prospects. This new CBR report adds to our unique portfolio of trusted industry analyses that enable our clients to assess the promising commercial areas in the life sciences industry and exploit key business opportunities.
-Understand the current status of the field of therapeutic Hyperhidrosis, and the relative clinical and commercial success of currently marketed products. -Assess the pipeline for Hyperhidrosis split by therapy area, vector type and intervention type, and stage of development. Additionally, a granular assessment of the pipeline is provided across the four major therapy areas for gene therapy: oncology, central nervous system disorders, ophthalmology, and genetic disorders. -Gain a picture of the current competitive landscape, with a detailed breakdown of companies actively involved in the gene therapy pipeline. -Understand the level of involvement in the landscape on the part of big pharma companies, and the extent to how Hyperhidrosis fit into the overall portfolios of companies in this field. -Understand the strategic consolidations landscape in Hyperhidrosis across the past decade
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
